In recent years, significant advances in neuroscience have fueled growth in the pipeline and increased pharmaceutical investment. While these advancements reduce scientific and regulatory risks, commercial challenges remain, making strategic decisions crucial for demonstrating value to stakeholders. In this 2024 recap, Lumanity’s Neuroscience strategy consulting team members highlight some of the most impactful breakthroughs and innovations, from new Alzheimer’s and schizophrenia treatments to non-opiate pain therapies and diagnostic advancements, reflecting the evolving landscape of neurological care.
Lumanity offers extensive experience-based strategic guidance and insights in the field of neuroscience. Our goal is to provide our clients with actionable solutions that de-risk and optimize the development and commercialization of therapies, ultimately improving the lives of patients who are impacted across a range of conditions.
